# US 2024/0197657 A1 · Ketorolac tromethamine compositions for treating or preventing ocular pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197657 A1
- Document ID: US20240197657A1
- Status: Published application
- Kind: A1
- Application number: 18/494,341
- Filed: 2023-10-25
- Published: 2024-06-20
- Earliest claimed: 2008-03-03
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Eldon Quinn Farnes; Mayssa Attar; Rhett M. Schiffman; Ching-Ming Chang; Richard S. Graham; Devin F. Welty
- Web page: https://patentgrep.com/patent/US20240197657A1

## CPC

- A61K 31/14: Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205)
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/186: {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.

## Claims

### Claim 1

A first composition for treating ocular pain and inflammation following cataract surgery comprising about 0.45% w/v ketorolac and about 0.5% w/v carboxymethyl cellulose.

### Claim 2 (depends on 1)

The first composition of claim 1 wherein the twice daily topical administration of the first composition to an eye increases the bioavailability of ketorolac in the eye relative to the twice daily topical administration of a second composition to an eye comprising about 0.5% ketorolac and no carboxymethyl cellulose.

### Claim 3 (depends on 1)

The first composition of claim 1 wherein the first composition comprises 0.45% w/v ketorolac tromethamine.

### Claim 4 (depends on 1)

The first composition of claim 1 wherein the first composition comprises at least one ingredient selected from the group consisting of sodium chloride, sodium citrate dihydrate, sodium hydroxide, hydrochloric acid and water.

### Claim 5 (depends on 4)

The first composition of claim 4 wherein the 0.5% w/v carboxymethyl cellulose is comprised of 0.325% w/v medium viscosity carboxymethyl cellulose and 0.175% w/v high viscosity carboxymethyl cellulose.

### Claim 6 (depends on 2)

The first composition of claim 2 wherein the first composition increases bioavailability of the ketorolac in the eye relative to a second composition by up to about 78%.

### Claim 7 (depends on 1)

The first composition of claim 1 wherein the first composition reduces ocular pain and inflammation following cataract surgery.

### Claim 8 (depends on 2)

The first composition of claim 2 wherein the first composition reduces ocular pain and inflammation following cataract surgery to a greater extent than the second composition.

### Claim 9

A first composition for treating ocular pain and inflammation comprising about 0.45% w/v ketorolac and about 0.5% w/v carboxymethyl cellulose, wherein the twice daily topical administration of the first composition to the eye increases bioavailability of ketorolac in the eye relative to the twice daily topical administration of a second composition comprising about 0.4% w/v ketorolac and no carboxymethyl cellulose.

### Claim 10 (depends on 9)

The composition of claim 9 wherein the first composition increases bioavailability of ketorolac in the eye relative to the second composition by up to about 185%.

### Claim 11 (depends on 9)

The first composition of claim 9 wherein the first composition comprises 0.45% w/v ketorolac tromethamine.

### Claim 12 (depends on 9)

The first composition of claim 9 wherein the first composition comprises 0.5% w/v carboxymethyl cellulose.

### Claim 13 (depends on 11)

The first composition of claim 11 wherein the first composition is used for treating pain and inflammation following cataract surgery.

### Claim 14 (depends on 12)

The first composition of claim 12 wherein the 0.5% w/v carboxymethyl cellulose is comprised of 0.325% w/v medium viscosity carboxymethyl cellulose and 0.175% w/v carboxymethyl cellulose.

### Claim 15 (depends on 9)

The first composition of claim 9 wherein the first composition further comprises sodium citrate dihydrate.

### Claim 16 (depends on 11)

The first composition of claim 11 wherein the first composition reduces ocular pain and inflammation following cataract surgery to a greater extent than the second composition.

### Claim 17 (depends on 9)

The first composition of claim 9 wherein the first composition reduces ocular pain and inflammation and results in less hyperemia than the second composition despite having a higher concentration of ketorolac.

### Claim 18 (depends on 9)

The first composition of claim 9 wherein the first composition reduces ocular pain and inflammation and results in less ocular burning and stinging than the second composition.

### Claim 19

A first composition for treating ocular pain and inflammation comprising 0.45% w/v ketorolac tromethamine and 0.5% w/v carboxymethyl cellulose, wherein the twice daily topical administration of the first composition to an eye increases the bioavailability of the ketorolac in the eye relative to the four times daily topical administration of a second composition to an eye comprising about 0.4% ketorolac tromethamine and no carboxymethyl cellulose.

### Claim 20 (depends on 19)

The first composition of claim 19 wherein administering the first composition twice a day to an eye of a patient increases the bioavailability of ketorolac in the eye by up to about two times greater relative to the second composition administered to an eye of a patient four times a day.

### Claim 21 (depends on 19)

The first composition of claim 19, wherein the first composition reduced ocular pain and inflammation with less ocular irritation as compared to the second composition.

### Claim 22 (depends on 19)

The first composition of claim 19, wherein the first composition reduces ocular pain and inflammation and results in less hyperemia than the second composition.

### Claim 23 (depends on 19)

The first composition of claim 19, wherein the first composition reduces ocular pain and inflammation and results in less ocular burning and stinging than the second composition.

### Claim 24 (depends on 19)

The first composition of claim 19 wherein the 0.5% w/v carboxymethyl cellulose is comprised of 0.325% w/v medium viscosity carboxymethyl cellulose and 0.175% w/v carboxymethyl cellulose.

### Claim 25

A composition for treating ocular pain and inflammation comprising 0.45% w/v ketorolac tromethamine, 0.5% w/v carboxy methyl cellulose, 0.7% w/v sodium chloride, 0.2% sodium citrate dihydrate and water.

### Claim 26 (depends on 25)

The composition of claim 25 wherein the pH of the composition is about 6.8.

### Claim 27 (depends on 25)

The composition of claim 25 wherein the 0.5% carboxy methyl cellulose is comprised of 0.325% w/v medium viscosity carboxymethyl cellulose and 0.175% w/v high viscosity carboxymethyl cellulose.

### Claim 28 (depends on 25)

The composition of claim 25 comprising sodium hydroxide and hydrochloric acid.

### Claim 29 (depends on 25)

The composition of claim 25 wherein the composition is used for treating ocular pain and inflammation following cataract surgery.
